A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression | Anesthesiology | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Merikangas  KRAkiskal  HSAngst  JGreenberg  PEHirschfeld  RMPetukhova  MKessler  RC Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.  Arch Gen Psychiatry 2007;64 (5) 543- 552PubMedGoogle ScholarCrossref
Calabrese  JRHuffman  RFWhite  RLEdwards  SThompson  TRAscher  JAMonaghan  ETLeadbetter  RA Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials.  Bipolar Disord 2008;10 (2) 323- 333PubMedGoogle ScholarCrossref
Sachs  GSNierenberg  AACalabrese  JRMarangell  LBWisniewski  SRGyulai  LFriedman  ESBowden  CLFossey  MDOstacher  MJKetter  TAPatel  JHauser  PRapport  DMartinez  JMAllen  MHMiklowitz  DJOtto  MWDennehy  EBThase  ME Effectiveness of adjunctive antidepressant treatment for bipolar depression.  N Engl J Med 2007;356 (17) 1711- 1722PubMedGoogle ScholarCrossref
Nierenberg  AAOstacher  MJCalabrese  JRKetter  TAMarangell  LBMiklowitz  DJMiyahara  SBauer  MSThase  MEWisniewski  SRSachs  GS Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.  Am J Psychiatry 2006;163 (2) 210- 216PubMedGoogle ScholarCrossref
Weisler  RHCalabrese  JRThase  MEArvekvist  RStening  GPaulsson  BSuppes  T Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies.  J Clin Psychiatry 2008;69 (5) 769- 782PubMedGoogle ScholarCrossref
Calabrese  JRKeck  PE  JrMacfadden  WMinkwitz  MKetter  TAWeisler  RHCutler  AJ McCoy  RWilson  EMullen  J A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.  Am J Psychiatry 2005;162 (7) 1351- 1360PubMedGoogle ScholarCrossref
Thase  MEMacfadden  WWeisler  RHChang  WPaulsson  BKhan  ACalabrese  JRBOLDER II Study Group, Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).  J Clin Psychopharmacol 2006;26 (6) 600- 609PubMedGoogle ScholarCrossref
Machado-Vieira  RSalvadore  GLuckenbaugh  DAManji  HKZarate  CA  Jr Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.  J Clin Psychiatry 2008;69 (6) 946- 958PubMedGoogle ScholarCrossref
Jick  HKaye  JAJick  SS Antidepressants and the risk of suicidal behaviors.  JAMA 2004;292 (3) 338- 343PubMedGoogle ScholarCrossref
Nock  MKHwang  ISampson  NKessler  RCAngermeyer  MBeautrais  ABorges  GBromet  EBruffaerts  Rde Girolamo  Gde Graaf  RFlorescu  SGureje  OHaro  JMHu  CHuang  YKaram  EGKawakami  NKovess  VLevinson  DPosada-Villa  JSagar  RTomov  TViana  MCWilliams  DR Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys.  PLoS Med 2009;6 (8) e1000123PubMedGoogle ScholarCrossref
Martinowich  KSchloesser  RJManji  HK Bipolar disorder: from genes to behavior pathways.  J Clin Invest 2009;119 (4) 726- 736PubMedGoogle ScholarCrossref
Zarate  CA  JrSingh  JManji  HK Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder.  Biol Psychiatry 2006;59 (11) 1006- 1020PubMedGoogle ScholarCrossref
Law  AJDeakin  JF Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses.  Neuroreport 2001;12 (13) 2971- 2974PubMedGoogle ScholarCrossref
McCullumsmith  REKristiansen  LVBeneyto  MScarr  EDean  BMeador-Woodruff  JH Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder.  Brain Res 2007;1127 (1) 108- 118PubMedGoogle ScholarCrossref
Woo  TUWalsh  JPBenes  FM Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.  Arch Gen Psychiatry 2004;61 (7) 649- 657PubMedGoogle ScholarCrossref
Martucci  LWong  AHDe Luca  VLikhodi  OWong  GWKing  NKennedy  JL N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels.  Schizophr Res 2006;84 (2-3) 214- 221PubMedGoogle ScholarCrossref
Mundo  ETharmalingham  SNeves-Pereira  MDalton  EJMacciardi  FParikh  SVBolonna  AKerwin  RWArranz  MJMakoff  AJKennedy  JL Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder.  Mol Psychiatry 2003;8 (2) 241- 245PubMedGoogle ScholarCrossref
Brennan  BPHudson  JIJensen  JE McCarthy  JRoberts  JLPrescot  APCohen  BMPope  HG  JrRenshaw  PFOngür  D Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.  Neuropsychopharmacology 2010;35 (3) 834- 846PubMedGoogle ScholarCrossref
Zarate  CA  JrQuiroz  JASingh  JBDenicoff  KDDe Jesus  GLuckenbaugh  DACharney  DSManji  HK An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.  Biol Psychiatry 2005;57 (4) 430- 432PubMedGoogle ScholarCrossref
Du  JSuzuki  KWei  YWang  YBlumenthal  RChen  ZFalke  CZarate  CA  JrManji  HK The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders.  Neuropsychopharmacology 2007;32 (4) 793- 802PubMedGoogle ScholarCrossref
Layer  RTPopik  POlds  TSkolnick  P Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715).  Pharmacol Biochem Behav 1995;52 (3) 621- 627PubMedGoogle ScholarCrossref
Meloni  DGambarana  CDe Montis  MGDal Pra  PTaddei  ITagliamonte  A Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats.  Pharmacol Biochem Behav 1993;46 (2) 423- 426PubMedGoogle ScholarCrossref
Moryl  EDanysz  WQuack  G Potential antidepressive properties of amantadine, memantine and bifemelane.  Pharmacol Toxicol 1993;72 (6) 394- 397PubMedGoogle ScholarCrossref
Papp  MMoryl  E Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression.  Eur J Pharmacol 1994;263 (1-2) 1- 7PubMedGoogle ScholarCrossref
Przegaliński  ETatarczynska  EDeren-Wesolek  AChojnacka-Wojcik  E Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist.  Neuropharmacology 1997;36 (1) 31- 37PubMedGoogle ScholarCrossref
Trullas  RSkolnick  P Functional antagonists at the NMDA receptor complex exhibit antidepressant actions.  Eur J Pharmacol 1990;185 (1) 1- 10PubMedGoogle ScholarCrossref
Krystal  JHSanacora  GBlumberg  HAnand  ACharney  DSMarek  GEpperson  CNGoddard  AMason  GF Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.  Mol Psychiatry 2002;7(suppl 1)S71- S80PubMedGoogle ScholarCrossref
Sanacora  GZarate  CAKrystal  JHManji  HK Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.  Nat Rev Drug Discov 2008;7 (5) 426- 437PubMedGoogle ScholarCrossref
Zarate  CAQuiroz  JPayne  JManji  HK Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders.  Psychopharmacol Bull 2002;36 (4) 35- 83PubMedGoogle Scholar
Krystal  JHKarper  LPSeibyl  JPFreeman  GKDelaney  RBremner  JDHeninger  GRBowers  MB  JrCharney  DS Subanesthetic effects of the noncompetitive NMDAantagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses.  Arch Gen Psychiatry 1994;51 (3) 199- 214PubMedGoogle ScholarCrossref
First  MBSpitzer  RLGibbon  MWilliams  AR Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P).  New York, NY: New York State Psychiatric Institute, Biometrics Research; 2001
Sackeim  HA The definition and meaning of treatment-resistant depression.  J Clin Psychiatry 2001;62(suppl 16)10- 17PubMedGoogle Scholar
Berman  RMCappiello  AAnand  AOren  DAHeninger  GRCharney  DSKrystal  JH Antidepressant effects of ketamine in depressed patients.  Biol Psychiatry 2000;47 (4) 351- 354PubMedGoogle ScholarCrossref
Zarate  CA  JrSingh  JBCarlson  PJBrutsche  NEAmeli  RLuckenbaugh  DAChar ney  DSManji  HK A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.  Arch Gen Psychiatry 2006;63 (8) 856- 864PubMedGoogle ScholarCrossref
Hamilton  M A rating scale for depression.  J Neurol Neurosurg Psychiatry 1960;2356- 62PubMedGoogle ScholarCrossref
Beck  ATBeamesderfer  A Assessment of depression: the depression inventory.  Mod Probl Pharmacopsychiatry 1974;7 (0) 151- 169PubMedGoogle Scholar
Aitken  RC Measurement of feelings using visual analogue scales.  Proc R Soc Med 1969;62 (10) 989- 993PubMedGoogle Scholar
Hamilton  M The assessment of anxiety states by rating.  Br J Med Psychol 1959;32 (1) 50- 55PubMedGoogle ScholarCrossref
Overall  JEGorham  DR The Brief Psychiatric Rating Scale.  Psychol Rep 1962;10799- 812Google ScholarCrossref
Bremner  JDKrystal  JHPutnam  FWSouthwick  SMMarmar  CCharney  DSMazure  CM Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).  J Trauma Stress 1998;11 (1) 125- 136PubMedGoogle ScholarCrossref
Young  RCBiggs  JTZiegler  VEMeyer  DA A rating scale for mania: reliability, validity and sensitivity.  Br J Psychiatry 1978;133429- 435PubMedGoogle ScholarCrossref
White  PFSchuttler  JShafer  AStanski  DRHorai  YTrevor  AJ Comparative pharmacology of the ketamine isomers: studies in volunteers.  Br J Anaesth 1985;57 (2) 197- 203PubMedGoogle ScholarCrossref
Moghaddam  BAdams  BVerma  ADaly  D Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.  J Neurosci 1997;17 (8) 2921- 2927PubMedGoogle Scholar
Maeng  SZarate  CA  JrDu  JSchloesser  RJ McCammon  JChen  GManji  HK Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.  Biol Psychiatry 2008;63 (4) 349- 352PubMedGoogle ScholarCrossref
Altamura  ACDell’Osso  BBuoli  MZanoni  SMundo  E Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study.  J Clin Psychopharmacol 2008;28 (4) 406- 410PubMedGoogle ScholarCrossref
Furey  MLDrevets  WC Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.  Arch Gen Psychiatry 2006;63 (10) 1121- 1129PubMedGoogle ScholarCrossref
Preskorn  SHBaker  BKolluri  SMenniti  FSKrams  MLanden  JW An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.  J Clin Psychopharmacol 2008;28 (6) 631- 637PubMedGoogle ScholarCrossref
Szuba  MPAmsterdam  JDFernando  AT  IIIGary  KAWhybrow  PCWinokur  A Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression.  J Clin Psychopharmacol 2005;25 (4) 325- 330PubMedGoogle ScholarCrossref
Anand  ACharney  DSOren  DABerman  RMHu  XSCappiello  AKrystal  JH Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.  Arch Gen Psychiatry 2000;57 (3) 270- 276PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    2 Comments for this article
    Might Ketamine Itself be the Answer?
    Scott A. Irwin, MD, PhD | The Institute for Palliative Medicine at San Diego Hospice
    I have been excited and inspired by the works of Dr. Zarate and others investigating ketamine as a rapid treatment for depression. This work highlights the need for better and more rapid depression treatments, as well as for further investigations into the role of glutamate in depressive syndromes. I would like to address two conclusions that are surfacing from this work. The first is that drug companies need to pursue new agents targeting this mechanism, and the second is the need for and feasibility of using the intravenous route. I wonder if either of those is necessary.
    at this dosing level has evidence for the successful treatment of cancer and post-operative pain with few side effects,(1-5) even when given via the oral,(6,7) sublingual,(8) or intranasal routes.(9) In fact, I wonder if first pass metabolism to norketamine improves efficacy, as norketamine is believed to be equipotent to ketamine as an analgesic and has a longer half-life.
    Recently, we published two cases of depression rapidly treated with oral ketamine, with no adverse reactions and good effect for anxiety as well.(10)
    So, might ketamine already be our answer? It is cheap, available, can be administered by many routes, and has increasing evidence of effectiveness with few side effects.
    1. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg. Aug 2004;99(2):482-495, table of contents.
    2. Lossignol DA, Obiols-Portis M, Body JJ. Successful use of ketamine for intractable cancer pain. Support Care Cancer. Mar 2005;13(3):188-193.
    3. Fitzgibbon EJ, Hall P, Schroder C, Seely J, Viola R. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage. Feb 2002;23(2):165-170.
    4. Fine PG. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage. Apr 1999;17(4):296-300.
    5. Clark JL, Kalan GE. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage. May 1995;10(4):310-314.
    6. Kannan TR, Saxena A, Bhatnagar S, Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage. Jan 2002;23(1):60-65.
    7. Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology. Jun 1999;90(6):1528-1533.
    8. Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage. Nov 2005;30(5):485-491.
    9. Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. Mar 2004;108(1-2):17-27.
    10. Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med. Jul;13(7):903-908.

    Conflict of Interest: Career Development Support provided by the National Palliative Care Research Center; no other potential conflicts or relevant financial interests.
    Cost Effectiveness of IV Ketamine for Treatment-Resistant Bipolar Depression
    Jon E Berner, MD, PhD | Woodinville Psychiatric Assoc.
    Dear Sir, The NIMH Mood Disorders group recently reported in the August issue successful extension of their IV ketamine treatment protocol from initial work with unipolar depression to bipolar depression.1 They note in the discussion section limitations related to a small sample size, limited generalizability due to narrow inclusion criteria, and absent data regarding maintenance dosing protocols. Our experience with ketamine in a fee-for-service community setting directly addresses the concerns raised in the discussion section but also raises questions about reliance on an IV route of administration.
    Cost matters. The IV route is much more expensive than the
    self administered oral2 or intranasal route3 commonly used in chronic pain settings. Intranasal ketamine is inexpensive; a two week supply is currently $84.00 for 300# 10 mg. doses at the local compounding pharmacy. In contrast, the cost for the IV setup is $150-$250 in community clinics presumably dosed every 3-7 days. Given relative minimal economic barriers to self-administered use, it is possible to gather useful clinical experience in the community with the drug in short periods of time, in contrast to the 2.5 year recruitment period for 18 patients in the NIMH trials. A retrospective review of IN ketamine trials, largely in refractory pain patients in our clinic during a nine month period from 2007 to 2008, reveals the complementary data requested by the discussion section: a large sample size (59/110 patients with a bipolar diagnosis), extensive comorbity (average number of psychotropic medications 2.8), and an average maintenance intranasal dose (217 mg). Probability of refill of the initial prescription after a 30 day trial (64%), suggests potential equivalent efficacy to the IV route (54%).
    Dose matters. IV dosing, with the locus of control fixed with the physician, inherently degrades the patient incentives to maximize efficacy. The variance in self-administered maintenance IN dosing (118 mg.) relative to mean (217 mg.) confirms a clinical experience, that optimal maintenance dosing requires titration. Some patients, given control of their dosing, can learn to tolerate mild perceptual distortions or dizziness.
    Cost-effectiveness of clinical treatment has important implications for understanding the link between addiction and NMDA activity. Clinical concern has typically focused on possible addiction to self-administered ketamine despite a very low prevalence relative to worldwide access4 and prominent elements of pseudo-addiction rather than euphoria in self-reports of dependent individuals.5,6 This focus tends to overshadow the observed strong link between a family history of alcohol dependence and ketamine responsiveness as observed in the structured trials at NIMH.7 Given the highly polygenetic nature of alcohol dependence, a statistical argument could be made for a follow-up community research strategy based on large numbers of patients and a broad variance in the scientific paradigms of interested investigators. The nasal and oral forms of ketamine, cheaper and more finely titrated, may advance addiction research and treatment more quickly.
    Jon Berner, MD, PhD
    1. Diazgranados N, Ibrahim L, Brutsche N, Newberg A, Kronstein P, Khalife S, Kammerer W, Quezado Z, Luckkenbaugh D, Salvadore G, Machado-Vieira R, Manji H, Zarate C. A randomized add-on trial on an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010; 67(8):793-802.
    2. Cvrèek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med. 2008 Mar; 9(2):253-7.
    3. Huge V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, Azad S. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain. 2010 Apr;14(4):387-94. Epub 2009 Sep 3.
    4. Degenhardt L, Dunn M. The epidemiology of GHB and ketamine use in an Australian household survey. Int J Drug Policy. 2008 Aug;19(4):311-6. Epub 2007 Oct 24.
    5. Reynaud-Maurupt C, Bello P, Akoka S, Toufik A. Characteristics and behaviors of ketamine users in France in 2003. J Psychoactive Drugs. 2007 Mar;39(1):1-11.
    6. Brunk D. Communication difficulties cited by users of ketamine. Clinical Psychiatry News. 2008; 3:42.
    7. Phelps L, Butsche N, Moral J, Luckenbaugh D, Manj H, Zarate Jr C. Family history of alcohol dependence and initial antidepressant response to a N-methyl-D-aspartate. Biol Psychiatry. 2009 Jan 15;65(2):181-4. Epub 2008 Nov 8.

    Conflict of Interest: None declared
    Original Article
    August 2010

    A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

    Author Affiliations

    Author Affiliations: Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland. Dr Newberg is now at the University of North Carolina at Chapel Hill; Dr Kronstein is now with the US Food and Drug Administration, Silver Spring, Maryland; Dr Khalife is now at the Manhattan Psychiatric Center, New York, New York; and Dr Manji is now with Johnson & Johnson Pharmaceuticals, New Brunswick, New Jersey.

    Arch Gen Psychiatry. 2010;67(8):793-802. doi:10.1001/archgenpsychiatry.2010.90

    Context  Existing therapies for bipolar depression have a considerable lag of onset of action. Pharmacological strategies that produce rapid antidepressant effects—for instance, within a few hours or days—would have an enormous impact on patient care and public health.

    Objective  To determine whether an N-methyl-D-aspartate–receptor antagonist produces rapid antidepressant effects in subjects with bipolar depression.

    Design  A randomized, placebo-controlled, double-blind, crossover, add-on study conducted from October 2006 to June 2009.

    Setting  Mood Disorders Research Unit at the National Institute of Mental Health, Bethesda, Maryland.

    Patients  Eighteen subjects with DSM-IV bipolar depression (treatment-resistant).

    Interventions  Subjects maintained at therapeutic levels of lithium or valproate received an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days 2 weeks apart. The Montgomery-Asberg Depression Rating Scale was used to rate subjects at baseline and at 40, 80, 110, and 230 minutes and on days 1, 2, 3, 7, 10, and 14 postinfusion.

    Main Outcome Measures  Change in Montgomery-Asberg Depression Rating Scale primary efficacy measure scores.

    Results  Within 40 minutes, depressive symptoms significantly improved in subjects receiving ketamine compared with placebo (d = 0.52, 95% confidence interval [CI], 0.28-0.76); this improvement remained significant through day 3. The drug difference effect size was largest at day 2 (d = 0.80, 95% CI, 0.55-1.04). Seventy-one percent of subjects responded to ketamine and 6% responded to placebo at some point during the trial. One subject receiving ketamine and 1 receiving placebo developed manic symptoms. Ketamine was generally well tolerated; the most common adverse effect was dissociative symptoms, only at the 40-minute point.

    Conclusion  In patients with treatment-resistant bipolar depression, robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist.

    Trial Registration  clinicaltrials.gov Identifier: NCT00088699